Myriad Genetics buy DerAlmanach100000
Start price
03.06.25
/
50%
€4.34
Target price
03.07.25
-
Performance (%)
8.29%
End price
04.06.25
€4.70
Summary
This prediction ended on 04.06.25 with a price of €4.70. With a performance of 8.29%, the BUY prediction by DerAlmanach100000 for Myriad Genetics closed with a slight gain. DerAlmanach100000 has a follow-up prediction for Myriad Genetics where he still thinks Myriad Genetics is a Buy. DerAlmanach100000 has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | -5.455% | -5.455% |
| iShares Core DAX® | -1,10 % | -6,08 % |
| iShares Nasdaq 100 | 0,33 % | 2,33 % |
| iShares Nikkei 225® | -1,08 % | -7,99 % |
| iShares S&P 500 | -0,06 % | 0,88 % |
According to DerAlmanach100000 what are the pros and cons of Myriad Genetics for the foreseeable future?
Pros
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Very Future proof/growth oriented business model
Market Leader or Top 3
Cons
Comments by DerAlmanach100000 for this prediction
In the thread Trading Myriad Genetics
Current prediction by DerAlmanach100000 for Myriad Genetics
Myriad Genetics
Start price
Target price
Perf. (%)
€6.30
23.11.25
23.11.25
-
23.11.28
23.11.28
-33.97%
13.03.26
13.03.26
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Stopped prediction by DerAlmanach100000 for Myriad Genetics
Myriad Genetics
Start price
Target price
Perf. (%)
€4.44
05.06.25
05.06.25
-
05.06.28
05.06.28
8.56%
06.08.25
06.08.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Myriad Genetics
Start price
Target price
Perf. (%)
€3.60
17.05.25
17.05.25
-
17.05.28
17.05.28
6.67%
28.05.25
28.05.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued